Last reviewed · How we verify
Imaging ovarian cancer and malignant lesions — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cytalux | PAFOLACIANINE | On Target Labs | Optical Imaging Agent | Folate receptor alpha | 2021-01-01 | |
| Cytalux | Cytalux | Ann & Robert H Lurie Children's Hospital of Chicago | Folate receptor alpha |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Ann & Robert H Lurie Children's Hospital of Chicago · 1 drug in Imaging ovarian cancer and malignant lesions
- On Target Labs · 1 drug in Imaging ovarian cancer and malignant lesions
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Imaging ovarian cancer and malignant lesions:
- Imaging ovarian cancer and malignant lesions treatment updates — RSS
- Imaging ovarian cancer and malignant lesions treatment updates — Atom
- Imaging ovarian cancer and malignant lesions treatment updates — JSON
Cite this brief
Drug Landscape (2026). Imaging ovarian cancer and malignant lesions — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/imaging-ovarian-cancer-and-malignant-lesions. Accessed 2026-06-10.
Related
- Imaging ovarian cancer and malignant lesions full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing